Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time

Pain Medicine (United States)

Volumn 16, Issue 8, 2015, Pages 1551-1565

  Coyne, Karin S ^a   Margolis, Mary Kay ^a   Yeomans, Karen ^b   King, Frederic R ^c   Chavoshi, Soheil ^c   Payne, Krista A ^b   LoCasale, Robert J ^c  

^a EVIDERA   (United States)

^b Express Scripts   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Constipation; Laxatives; Opioid; Pain; Symptoms

Indexed keywords

LAXATIVE; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CANADA; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; FLUID THERAPY; FOLLOW UP; GERMANY; HIGH FIBER DIET; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRESCRIPTION; PREVALENCE; PROSPECTIVE STUDY; SYMPTOM; UNITED KINGDOM; UNITED STATES; AGED; CHEMICALLY INDUCED; COST OF ILLNESS; DRUG UTILIZATION; GREAT BRITAIN; HEALTH SURVEY; MIDDLE AGED; QUALITY OF LIFE; SOCIOECONOMICS;

ADULT; AGED; ANALGESICS, OPIOID; CANADA; CHRONIC PAIN; CONSTIPATION; COST OF ILLNESS; DRUG UTILIZATION; FEMALE; GERMANY; GREAT BRITAIN; HEALTH SURVEYS; HUMANS; LAXATIVES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84939568499     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12724     Document Type: Article

References (22)

1. Aparasu R, McCoy RA, Weber C, Mair D, Parasuraman TV. Opioid-induced emesis among hospitalized nonsurgical patients: Effect on pain and quality of life. J Pain Symptom Manage 1999;18(4):280-8.
2. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10(1):35-42. doi:10.1111/j.1526-4637.2008.00495.x.
3. Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: A systematic literature review. J Opioid Manage 2010;6(4):269-89.
4. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: Results from a population-based survey. Aliment Pharmacol Ther 2008;27(12):1224-32. doi:10.1111/j.1365-2036.2008.03689.x.
5. Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: Descriptive analysis of baseline patient-reported outcomes and retrospective chart review. ClinicoEcon Outcomes Res 2014;6:269-81. doi:10.2147/CEOR.S61602.
6. Hess B, Bernardi M, Klotz HP. Attitude of Swiss physicians towards opioid-induced constipation: A national survey. Eur J Intern Med 2011;22(5):527-31. doi:10.1016/j.ejim.2011.02.014.
7. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract 2007;61(7):1181-7. doi:10.1111/j.1742-1241.2007.01415.x.
8. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322(7295):1154-8.
9. Brown RT, Zuelsdorff M, Fleming M. Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manage 2006;2(3):137-46.
10. Penning-van Beest FJ, van den Haak P, et al. Quality of life in relation to constipation among opioid users. J Med Econ 2010;13(1):129-35. doi:10.3111/13696990903584436.
11. Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: Prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 2010;14(12):1045-50.
12. Singh S, Rao SS. Pharmacologic management of chronic constipation. Gastroenterol Clin North Am 2010;39(3):509-27. doi:10.1016/j.gtc.2010.08.001.
13. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-8S.
14. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011(1):CD003448. doi:10.1002/14651858.CD003448.pub3.
15. Muller-Lissner S, Tack J, Feng Y, Schenck F, Specht Gryp R. Levels of satisfaction with current chronic constipation treatment options in Europe-An internet survey. Aliment Pharmacol Ther 2013;37(1):137-45. doi:10.1111/apt.12124.
16. Dinning PG, Hunt L, Lubowski DZ, et al. The impact of laxative use upon symptoms in patients with proven slow transit constipation. BMC Gastroenterol 2011;11:121. doi:10.1186/1471-230X-11-121.
17. Frank L, Kleinman L, Farup C, Taylor L, Miner P, Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34(9):870-7.
18. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005;40(5):540-51. doi:10.1080/00365520510012208.
19. McMillan SC, Tofthagen C, Small B, Karver S, Craig D. Trajectory of medication-induced constipation in patients with cancer. Oncol Nurs Forum 2013;40(3):E92-100. doi:10.1188/13.ONF.E92-E100.
20. McCarney R, Warner J, Iliffe S, et al. The Hawthorne Effect: A randomised, controlled trial. BMC Med Res Methodol 2007;7:30. doi:10.1186/1471-2288-7-30.
21. Michna E, Cheng WY, Korves C, et al. Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management. Pain Med 2014;15(1):79-92. doi:10.1111/pme.12233.
22. Bhinder S, Chowdhury N, Granton J, et al. Feasibility of internet-based health-related quality of life data collection in a large patient cohort. J Med Internet Res 2010;12(3):e35. doi:10.2196/jmir.1214.